Search Results

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acquisition of privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device.

Haemonetics Corporation has completed its previously announced acquisition of OpSens Inc.

Haemonetics Corporation, a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP® XL mid-bore venous closure device.

Haemonetics Corporation announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Haemonetics Corporation announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024, are available on its Investor Relations website.

Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024.

Haemonetics Corporation announced that it has entered into a definitive agreement to acquire privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device, the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency cardiac ablation procedures.

Haemonetics Corporation and OpSens, Inc. announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate.

Haemonetics Corporation, a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced that it has received 510 clearance from the U.S. Food and Drug Administration for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge.